Literature DB >> 22038905

High-resolution analysis of alterations in medullary thyroid carcinoma genomes.

Karin Flicker1, Peter Ulz, Harald Höger, Petra Zeitlhofer, Oskar A Haas, Annemarie Behmel, Wolfgang Buchinger, Christian Scheuba, Bruno Niederle, Roswitha Pfragner, Michael R Speicher.   

Abstract

Hereditary and sporadic medullary thyroid carcinoma (MTC) are closely associated with RET proto-oncogene mutations. However, the role of additional changes in the tumor genomes remains unclear. Our objective was the identification of chromosomal regions involved in MTC tumorigenesis and to assess their significance by using MTC-derived cell lines. We used array-CGH (comparative genomic hybridization) to map chromosomal imbalances in 52 primary tumors and ten metastases. Eleven tumors (11/52, 21%) were hereditary and 41 (41/52, 79%) were sporadic. Among the latter, 15 tumors (15/41, 37%) harbored RET mutations. Furthermore, we characterized five MTC cell lines in detail and evaluated the tumorigenicity by severe combined immunodeficiency (SCID)-mouse experiments. Most MTCs had only few copy number changes, and losses of chromosomes 1p, 4q, 19p and 22q were observed most frequently. The number of chromosomal aberrations increased in metastases. Twenty-three percent (12/52) of the primary tumors did not even show any chromosomal gains and losses. We injected three cell lines (two of these were without chromosomal changes and pathogenic RET mutations) into immune deficient SCID mice, and in each case, we observed rapid tumor growth at the injection sites. Our data suggest that MTCs--in contrast to most other tumor entities--do not acquire a multitude of genomic imbalances. SCID mouse experiments performed with chromosomally normal cell lines and without RET mutations suggest that presently unknown submicroscopic genomic changes are sufficient in MTC tumorigenesis.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22038905     DOI: 10.1002/ijc.26494

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  12 in total

1.  Role of CDKN2C Fluorescence In Situ Hybridization in the Management of Medullary Thyroid Carcinoma.

Authors:  Maha El Naofal; Adriel Kim; Hui Yi Yon; Mohamed Baity; Zhao Ming; Jacquelin Bui-Griffith; Zhenya Tang; Melissa Robinson; Elizabeth G Grubbs; Gilbert J Cote; Peter Hu
Journal:  Ann Clin Lab Sci       Date:  2017-09       Impact factor: 1.256

Review 2.  Thyroid C-Cell Biology and Oncogenic Transformation.

Authors:  Gilbert J Cote; Elizabeth G Grubbs; Marie-Claude Hofmann
Journal:  Recent Results Cancer Res       Date:  2015

3.  Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.

Authors:  Elizabeth G Grubbs; Michelle D Williams; Paul Scheet; Selina Vattathil; Nancy D Perrier; Jeffrey E Lee; Robert F Gagel; Tao Hai; Lei Feng; Maria E Cabanillas; Gilbert J Cote
Journal:  Thyroid       Date:  2016-10-18       Impact factor: 6.568

4.  ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

Authors:  Rozita Bagheri-Yarmand; Michelle D Williams; Elizabeth G Grubbs; Robert F Gagel
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

5.  Reduced Retinoblastoma Protein Expression Is Associated with Decreased Patient Survival in Medullary Thyroid Cancer.

Authors:  Anisley Valenciaga; Elizabeth G Grubbs; Kyle Porter; Paul E Wakely; Michelle D Williams; Gilbert J Cote; Vasyl V Vasko; Motoyasu Saji; Matthew D Ringel
Journal:  Thyroid       Date:  2017-12       Impact factor: 6.568

6.  The role of Cdk5 in neuroendocrine thyroid cancer.

Authors:  Karine Pozo; Emely Castro-Rivera; Chunfeng Tan; Florian Plattner; Gert Schwach; Veronika Siegl; Douglas Meyer; Ailan Guo; Justin Gundara; Gabriel Mettlach; Edmond Richer; Jonathan A Guevara; Li Ning; Anjali Gupta; Guiyang Hao; Li-Huei Tsai; Xiankai Sun; Pietro Antich; Stanley Sidhu; Bruce G Robinson; Herbert Chen; Fiemu E Nwariaku; Roswitha Pfragner; James A Richardson; James A Bibb
Journal:  Cancer Cell       Date:  2013-10-14       Impact factor: 31.743

7.  ATF4 loss of heterozygosity is associated with poor overall survival in medullary thyroid carcinoma.

Authors:  Michelle D Williams; Junsheng Ma; Elizabeth G Grubbs; Robert F Gagel; Rozita Bagheri-Yarmand
Journal:  Am J Cancer Res       Date:  2021-06-15       Impact factor: 6.166

8.  Differential expression of cell cycle regulators in CDK5-dependent medullary thyroid carcinoma tumorigenesis.

Authors:  Karine Pozo; Antje Hillmann; Alexander Augustyn; Florian Plattner; Tao Hai; Tanvir Singh; Saleh Ramezani; Xiankai Sun; Roswitha Pfragner; John D Minna; Gilbert J Cote; Herbert Chen; James A Bibb; Fiemu E Nwariaku
Journal:  Oncotarget       Date:  2015-05-20

9.  Anti-tumor effects of shikonin derivatives on human medullary thyroid carcinoma cells.

Authors:  Carina Hasenoehrl; Gert Schwach; Nassim Ghaffari-Tabrizi-Wizsy; Robert Fuchs; Nadine Kretschmer; Rudolf Bauer; Roswitha Pfragner
Journal:  Endocr Connect       Date:  2017-01-09       Impact factor: 3.335

10.  Putative BRAF activating fusion in a medullary thyroid cancer.

Authors:  Katayoon Kasaian; Sam M Wiseman; Blair A Walker; Jacqueline E Schein; Martin Hirst; Richard A Moore; Andrew J Mungall; Marco A Marra; Steven J M Jones
Journal:  Cold Spring Harb Mol Case Stud       Date:  2016-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.